(PHIA) Koninklijke Philips - Ratings and Ratios
Medical Imaging, Health Care, Personal Care, Diagnostic Equipment, Home Care
PHIA EPS (Earnings per Share)
PHIA Revenue
Description: PHIA Koninklijke Philips
Koninklijke Philips NV (PHIA) is a health technology company operating globally, with a presence in North America, Greater China, and other international markets. The company is segmented into Diagnosis & Treatment, Connected Care, and Personal Health, offering a diverse range of products and solutions.
The Diagnosis & Treatment segment provides diagnostic imaging solutions, including MRI, X-ray, and CT systems, as well as ultrasound and interventional X-ray systems. The Connected Care segment offers acute patient management, emergency care, and patient care management solutions, while the Personal Health segment provides consumer health products such as power toothbrushes, infant feeding, and grooming solutions.
From a financial perspective, Philips has a market capitalization of approximately €19.6 billion, with a forward P/E ratio of 13.85, indicating a relatively reasonable valuation. The companys Return on Equity (RoE) is 3.14%, which may be considered low, suggesting potential for improvement in profitability. To further analyze the companys performance, we can examine additional KPIs such as Revenue Growth, EBITDA Margin, and Debt-to-Equity ratio.
Some key performance indicators (KPIs) to monitor for Philips include: Revenue Growth (5-year average: 4-5%), EBITDA Margin (around 15-16%), and Debt-to-Equity ratio (approximately 0.5-0.6). These metrics can provide insights into the companys ability to drive top-line growth, maintain profitability, and manage its capital structure. Furthermore, Philips commitment to innovation and R&D is reflected in its R&D expenses as a percentage of sales (around 8-9%), which is relatively high compared to industry peers.
In terms of future prospects, Philips is well-positioned to benefit from the growing demand for health technology solutions, driven by aging populations and increasing healthcare expenditure. The companys diversified product portfolio and global presence provide a solid foundation for growth, and its focus on innovation and R&D is likely to drive long-term success.
PHIA Stock Overview
| Market Cap in USD | 27,030m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception |
PHIA Stock Ratings
| Growth Rating | 9.07% |
| Fundamental | 58.2% |
| Dividend Rating | 47.5% |
| Return 12m vs S&P 500 | -26.3% |
| Analyst Rating | - |
PHIA Dividends
| Dividend Yield 12m | 3.60% |
| Yield on Cost 5y | 2.79% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 80.1% |
| Payout Ratio | 63.9% |
PHIA Growth Ratios
| Growth Correlation 3m | 91.1% |
| Growth Correlation 12m | -59.3% |
| Growth Correlation 5y | -35.5% |
| CAGR 5y | 29.15% |
| CAGR/Max DD 3y | 0.86 |
| CAGR/Mean DD 3y | 3.55 |
| Sharpe Ratio 12m | 0.53 |
| Alpha | 0.00 |
| Beta | 0.986 |
| Volatility | 26.91% |
| Current Volume | 828.6k |
| Average Volume 20d | 1136.5k |
| Stop Loss | 23 (-3%) |
| Signal | -0.64 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (162.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -1.92pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.43% (prev 7.59%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.10b > Net Income 162.0m (YES >=105%, WARN >=100%) |
| Net Debt (6.60b) to EBITDA (1.08b) ratio: 6.13 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (950.6m) change vs 12m ago 1.76% (target <= -2.0% for YES) |
| Gross Margin 43.85% (prev 41.56%; Δ 2.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.94% (prev 61.52%; Δ 2.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.33 (EBITDA TTM 1.08b / Interest Expense TTM 323.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.30
| (A) 0.07 = (Total Current Assets 9.06b - Total Current Liabilities 7.20b) / Total Assets 26.38b |
| (B) 0.12 = Retained Earnings (Balance) 3.03b / Total Assets 26.38b |
| (C) 0.04 = EBIT TTM 1.08b / Avg Total Assets 27.93b |
| (D) 0.19 = Book Value of Equity 3.03b / Total Liabilities 15.97b |
| Total Rating: 1.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.20
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 1.48% = 0.74 |
| 3. FCF Margin 2.46% = 0.61 |
| 4. Debt/Equity 0.81 = 2.18 |
| 5. Debt/Ebitda 7.82 = -2.50 |
| 6. ROIC - WACC (= 6.22)% = 7.77 |
| 7. RoE 1.41% = 0.12 |
| 8. Rev. Trend -20.17% = -1.51 |
| 9. EPS Trend 35.79% = 1.79 |
What is the price of PHIA shares?
Over the past week, the price has changed by -1.86%, over one month by +0.55%, over three months by +21.64% and over the past year by -12.61%.
Is Koninklijke Philips a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PHIA is around 21.90 EUR . This means that PHIA is currently overvalued and has a potential downside of -7.67%.
Is PHIA a buy, sell or hold?
What are the forecasts/targets for the PHIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.8 | 13.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.7 | 4% |
PHIA Fundamental Data Overview
Market Cap EUR = 23.05b (23.05b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 1.82b EUR (Cash only, last quarter)
P/E Trailing = 150.25
P/E Forward = 14.7493
P/S = 1.291
P/B = 2.2017
P/EG = 0.3634
Beta = 0.832
Revenue TTM = 17.86b EUR
EBIT TTM = 1.08b EUR
EBITDA TTM = 1.08b EUR
Long Term Debt = 7.18b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.24b EUR (from shortLongTermDebt, last quarter)
Debt = 8.43b EUR (Calculated: Short Term 1.24b + Long Term 7.18b)
Net Debt = 6.60b EUR (from netDebt column, last quarter)
Enterprise Value = 29.66b EUR (23.05b + Debt 8.43b - CCE 1.82b)
Interest Coverage Ratio = 3.33 (Ebit TTM 1.08b / Interest Expense TTM 323.0m)
FCF Yield = 1.48% (FCF TTM 439.0m / Enterprise Value 29.66b)
FCF Margin = 2.46% (FCF TTM 439.0m / Revenue TTM 17.86b)
Net Margin = 0.91% (Net Income TTM 162.0m / Revenue TTM 17.86b)
Gross Margin = 43.85% ((Revenue TTM 17.86b - Cost of Revenue TTM 10.03b) / Revenue TTM)
Tobins Q-Ratio = 9.77 (Enterprise Value 29.66b / Book Value Of Equity 3.03b)
Interest Expense / Debt = 0.95% (Interest Expense 80.0m / Debt 8.43b)
Taxrate = 782.9% (set to none) (963.0m / 123.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.26 (Total Current Assets 9.06b / Total Current Liabilities 7.20b)
Debt / Equity = 0.81 (Debt 8.43b / last Quarter total Stockholder Equity 10.38b)
Debt / EBITDA = 7.82 (Net Debt 6.60b / EBITDA 1.08b)
Debt / FCF = 19.19 (Debt 8.43b / FCF TTM 439.0m)
Total Stockholder Equity = 11.49b (last 4 quarters mean)
RoA = 0.61% (Net Income 162.0m, Total Assets 26.38b )
RoE = 1.41% (Net Income TTM 162.0m / Total Stockholder Equity 11.49b)
RoCE = 5.77% (Ebit 1.08b / (Equity 11.49b + L.T.Debt 7.18b))
RoIC = 6.22% (Ebit 1.08b / (Assets 26.38b - Current Assets 9.06b))
WACC = unknown (E(23.05b)/V(31.48b) * Re(9.65%)) + (D(8.43b)/V(31.48b) * Rd(0.95%) * (1-Tc(none)))
Shares Correlation 3-Years: -24.24 | Cagr: -0.26%
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 63.55% ; FCFE base≈685.4m ; Y1≈450.0m ; Y5≈205.8m
Fair Price DCF = 3.33 (DCF Value 3.16b / Shares Outstanding 950.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 35.79 | EPS CAGR: 308.2% | SUE: 0.42 | # QB: 0
Revenue Correlation: -20.17 | Revenue CAGR: 0.24% | SUE: N/A | # QB: None